Inactivated COVID-19 vaccines to make a global impact.
作者信息
Iversen Patrick L, Bavari Sina
机构信息
Oregon State University, Corvallis, OR, USA.
Edge BioInnovation and Healion Bio, Frederick, MD, USA.
出版信息
Lancet Infect Dis. 2021 Jun;21(6):746-748. doi: 10.1016/S1473-3099(21)00020-7. Epub 2021 Feb 3.
Abstract
摘要
相似文献
1
Inactivated COVID-19 vaccines to make a global impact.灭活新冠疫苗将产生全球影响。
Lancet Infect Dis. 2021 Jun;21(6):746-748. doi: 10.1016/S1473-3099(21)00020-7. Epub 2021 Feb 3.
2
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
3
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.一项在 18-59 岁健康成年人中评估 SARS-CoV-2 灭活疫苗的有效性、安全性和免疫原性的 III 期、观察者盲法、随机、安慰剂对照研究：印度尼西亚的中期分析。
Vaccine. 2021 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24.
4
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.一种灭活全病毒 SARS-CoV-2 疫苗（克尔来福）的有效性和安全性：在土耳其进行的一项双盲、随机、安慰剂对照、3 期临床试验的中期结果。
Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
5
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.2 种灭活 SARS-CoV-2 疫苗对成人有症状 COVID-19 感染的效果：一项随机临床试验。
JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565.
6
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一种灭活严重急性呼吸综合征冠状病毒2疫苗（科兴新冠疫苗）在60岁及以上健康成年人中的安全性、耐受性和免疫原性：一项随机、双盲、安慰剂对照的1/2期临床试验
Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3.
7
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.在中国，一种灭活的 SARS-CoV-2 疫苗（国药 BBIBP-CorV）与四价裂解流感疫苗和 23 价肺炎球菌多糖疫苗联合接种的免疫原性和安全性：一项多中心、非劣效性、开放性、随机、对照、四期临床试验。
Vaccine. 2022 Aug 26;40(36):5322-5332. doi: 10.1016/j.vaccine.2022.07.033. Epub 2022 Jul 29.
8
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.《一种灭活全病毒 SARS-CoV-2 疫苗 TURKOVAC 在健康成年人中的安全性和免疫原性：随机、双盲、安慰剂对照的 1 期和 2 期临床试验的中期结果》。
Vaccine. 2023 Jan 9;41(2):380-390. doi: 10.1016/j.vaccine.2022.10.093. Epub 2022 Nov 22.
9
Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.在广州，灭活的 SARS-CoV-2 疫苗对 Delta 变异株感染的有效性：一项病例对照的真实世界研究。
Emerg Microbes Infect. 2021 Dec;10(1):1751-1759. doi: 10.1080/22221751.2021.1969291.
10
Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.灭活的 SARS-CoV-2 疫苗可在 HIV 感染者中引发免疫原性和 T 细胞反应。
Int Immunopharmacol. 2022 Jan;102:108383. doi: 10.1016/j.intimp.2021.108383. Epub 2021 Nov 18.
引用本文的文献
1
[SEPAR Recommendations for COVID-19 Vaccination in Patients With Respiratory Diseases].[呼吸系统疾病患者新冠病毒疫苗接种的SEPAR建议]
Open Respir Arch. 2021 Mar 22;3(2):100097. doi: 10.1016/j.opresp.2021.100097. eCollection 2021 Apr-Jun.
2
Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.SARS-CoV-2 刺突蛋白在灭活疫苗开发过程中的结构和免疫原性。
Viruses. 2023 Feb 9;15(2):480. doi: 10.3390/v15020480.
3
Contextualizing Wastewater-Based surveillance in the COVID-19 vaccination era.在新冠疫苗时代，使基于污水的监测具有背景意义。
Environ Int. 2023 Jan;171:107718. doi: 10.1016/j.envint.2022.107718. Epub 2022 Dec 23.
4
Current clinical status of new COVID-19 vaccines and immunotherapy.新型 COVID-19 疫苗和免疫疗法的当前临床状况。
Environ Sci Pollut Res Int. 2022 Oct;29(47):70772-70807. doi: 10.1007/s11356-022-22661-1. Epub 2022 Sep 5.
5
COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran.接种疫苗后的 COVID-19 病例、住院和死亡：伊朗伊斯兰共和国的队列事件监测研究。
Bull World Health Organ. 2022 Aug 1;100(8):474-483. doi: 10.2471/BLT.22.288073. Epub 2022 Jun 22.
6
Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infection.单细胞转录组图谱揭示 COVID-19 疫苗接种和自然 SARS-CoV-2 感染之间的独特免疫反应。
J Med Virol. 2022 Nov;94(11):5304-5324. doi: 10.1002/jmv.28012. Epub 2022 Jul 30.
7
Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules.新兴的 SARS-CoV-2 抗病毒策略：从解析病毒蛋白结构功能到疫苗、抗体和小分子药物的开发。
Int J Mol Sci. 2022 May 29;23(11):6083. doi: 10.3390/ijms23116083.
8
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.COVID-19 疫苗：免疫原性、当前研发进展和未来前景的系统评价。
Front Immunol. 2022 Apr 27;13:843928. doi: 10.3389/fimmu.2022.843928. eCollection 2022.
9
COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development.新冠病毒基因变体及其在疫苗研发中的潜在影响。
Microorganisms. 2022 Mar 10;10(3):598. doi: 10.3390/microorganisms10030598.
10
Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19.有或无新冠病毒病诊断的参与者接种两剂科兴新冠疫苗后的抗体反应。
Ir J Med Sci. 2022 Dec;191(6):2833-2838. doi: 10.1007/s11845-021-02883-x. Epub 2022 Jan 10.
本文引用的文献
1
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一种灭活严重急性呼吸综合征冠状病毒2疫苗（科兴新冠疫苗）在60岁及以上健康成年人中的安全性、耐受性和免疫原性：一项随机、双盲、安慰剂对照的1/2期临床试验
Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3.
2
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
3
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.追求有效 SARS-CoV-2（COVID-19）疫苗的进展与困境。
Front Immunol. 2020 Oct 2;11:579250. doi: 10.3389/fimmu.2020.579250. eCollection 2020.
4
Immunological considerations for COVID-19 vaccine strategies.针对 COVID-19 疫苗策略的免疫学考虑。
Nat Rev Immunol. 2020 Oct;20(10):615-632. doi: 10.1038/s41577-020-00434-6. Epub 2020 Sep 4.
5
Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.免疫反应随衰老而重塑：免疫衰老及其对 COVID-19 免疫反应的潜在影响。
Front Immunol. 2020 Aug 7;11:1748. doi: 10.3389/fimmu.2020.01748. eCollection 2020.
Zotero 插件